Tesla shares slip after third-quarter profit falls short of estimates
Investing.com - TD Cowen has raised its price target on Danaher (NYSE:DHR) to $260 from $250 while maintaining a Buy rating on the stock. The company, with a substantial market capitalization of $156 billion, currently trades at a P/E ratio of 47.18. According to InvestingPro analysis, the stock is trading above its Fair Value, reflecting high market expectations.
The firm cited potential for high single-digit earnings per share growth in 2026 despite modest organic growth projections of just over 3%.
TD Cowen noted that accelerated cost-cutting measures by Danaher could provide a cushion during what may be an easier recovery period in 2026, describing this as a "clearing event" for investors who believe in the company’s bioprocess-driven strategy.
The analyst acknowledged that while a bioprocess upturn is becoming evident, weak areas remain in the Life Sciences segment and China diagnostics business.
These weak spots have already been factored into Danaher’s guidance, according to TD Cowen, potentially creating a path for upside if conditions improve beyond current expectations.
In other recent news, Danaher Corporation announced its third-quarter earnings for 2025, exceeding analyst expectations. The company reported an adjusted earnings per share (EPS) of $1.89, surpassing the anticipated $1.72. Revenue for the quarter reached $6.05 billion, slightly higher than the forecasted $6 billion. These results indicate a 9.88% earnings surprise, showcasing Danaher’s strong performance. The company’s stock showed a positive response to these developments. Investors are likely keeping a close eye on Danaher’s future performance, given these recent results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.